AI Article Synopsis

  • Stroke is a leading cause of illness and death globally, and this study investigates how a year-long pharmaceutical care program impacts stroke patients.
  • Conducted as a randomized controlled trial in Türkiye, patients received either enhanced pharmaceutical care (which included medication support) or standard treatment, with outcomes measured after 12 months.
  • Results showed significant improvements in medication adherence (86.5% vs 47.1%), quality of life scores (184.9 vs 166.0), and lower stroke recurrence rates (2.2% vs 10.6%) in the care program group compared to usual care.

Article Abstract

Background: Stroke is a major cause of morbidity and mortality worldwide. Pharmaceutical care services play a significant role in managing the risk factors associated with stroke.

Aim: This study aimed to examine the effects of a one-year pharmaceutical care programme on medication adherence, quality of life and clinical outcomes of patients with stroke.

Method: This study was conducted as a randomised controlled trial at the neurology clinic of a university hospital in Türkiye. Patients were randomly assigned to either an intervention group or usual care group (IG vs UCG). A simple randomization method using computer-based random numbers was used to assign participants in a 1:1 ratio. The IG received pharmaceutical care including medication reconciliation, medication review and patient education in addition to routine health services. The medication adherence, quality of life and clinical parameters of the patients were evaluated at the beginning and the end of the 12th month.

Results: This study included 193 patients (89 and 104 patients in the IG and the UCG, respectively; mean age: 60.1 years), of whom 67.4% were male. At the one-year follow-up evaluation, the percentage of adherent patients (86.5% vs 47.1%, p < 0.001) and the total Stroke-Specific Quality of Life score (184.9 vs 166.0, p < 0.001) were higher in the IG than in the UCG. The stroke recurrence rate at the one-year follow-up (2.2% vs 10.6%, p = 0.044) was lower in the IG than in the UCG.

Conclusion: Pharmaceutical care services improved the medication adherence, quality of life and clinical outcomes of patients with stroke.

The Clinical Trial Registration: ClinicalTrials.gov Identifier: NCT06129318; Study Registration Date: 13 November 2023.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11096-024-01811-0DOI Listing

Publication Analysis

Top Keywords

pharmaceutical care
16
medication adherence
12
quality life
12
care services
8
services medication
8
clinical outcomes
8
randomised controlled
8
controlled trial
8
adherence quality
8
life clinical
8

Similar Publications

Background: This study analyzed the epidemiological trends of three significant respiratory infectious diseases in Taiwan: invasive pneumococcal disease (IPD), influenza with severe complications, and tuberculosis during post-COVID-19 pandemic period.

Methods: We utilized data from Taiwan's Centers for Disease Control and Prevention (CDC) website and classified the COVID-19 prevention policies into three phases for the year 2021, 2022, and 2023. We then performed a statistical analysis of reported case numbers for the three respiratory diseases during the 3-year period using the Kruskal-Wallis test, followed by joinpoint regression model for the identification of seasonal distribution and variation.

View Article and Find Full Text PDF

Mesenchymal stem cells (MSCs) have several important properties that make them desirable for regenerative medicine. These properties include immunomodulatory ability, growth factor production, and differentiation into various cell types. Despite extensive research and promising results in clinical trials, our understanding of MSC biology, their mechanism of action, and their targeted and routine use in clinics is limited.

View Article and Find Full Text PDF

In the EU, conditional marketing authorization is a pragmatic tool for early approval of a medicine that fulfills an unmet medical need. In the pharmaceutical legislation, an unmet medical need means that a condition lacks a satisfactory method for diagnosis, prevention, or treatment. If such satisfactory methods exist, the new medicinal product must hold a major therapeutic advantage for those affected, meaning that it must demonstrate an improvement in efficacy or safety over existing methods or, in exceptional cases, a major improvement in patient care.

View Article and Find Full Text PDF

Aim: Dynamic cancer control is a current health system priority, yet methods for achieving it are lacking. This study aims to review the application of system dynamics modeling (SDM) on cancer control and evaluate the research quality.

Methods: Articles were searched in PubMed, Web of Science, and Scopus from the inception of the study to November 15th, 2023.

View Article and Find Full Text PDF

The WOUND-Q is a patient-reported outcome measure for individuals with any type of chronic wound. This study aimed to identify patient and wound factors associated with the four WOUND-Q health-related quality of life (HRQL) scales: Life impact, Psychological, Sleep, and Social. Adults with a chronic wound were recruited internationally through clinical settings between August 2018 and May 2020, and through an online platform (i.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!